Gary K. Lee - 24 Feb 2023 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Scientific Officer
Signature: /s/ Hector Casab, as Attorney-in-Fact
Issuer symbol: LYEL
Transactions as of: 24 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 28 Feb 2023, 17:17:09 UTC
Previous filing: 14 Feb 2022
Next filing: 20 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	LYEL	Common Stock						4,702	24 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award	$0	+600,000		$0.000000	600,000	24 Feb 2023	Common Stock	600,000	$2.13	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
F2	12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.